Foresite Capital Management IV’s Cymabay Therapeutics CBAY Stock Holding History

Foresite Capital Management IV’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,787,094	Closed	-$26.6M	–	7
2023 Q3	$26.6M	Hold	1,787,094	–	–	14.8%	2
2023 Q2	$19.6M	Hold	1,787,094	–	–	9.62%	6
2023 Q1	$15.6M	Hold	1,787,094	–	–	8.09%	7
2022 Q4	$11.2M	Hold	1,787,094	–	–	4.79%	7
2022 Q3	$6.25M	Hold	1,787,094	–	–	2.01%	7
2022 Q2	$5.27M	Hold	1,787,094	–	–	1.42%	7
2022 Q1	$5.56M	Hold	1,787,094	–	–	1.55%	8
2021 Q4	$6.04M	Hold	1,787,094	–	–	1.24%	9
2021 Q3	$6.52M	Hold	1,787,094	–	–	0.96%	10
2021 Q2	$7.79M	Hold	1,787,094	–	–	1.05%	11
2021 Q1	$8.11M	Hold	1,787,094	–	–	0.97%	11
2020 Q4	$10.3M	Hold	1,787,094	–	–	1.11%	11
2020 Q3	$12.9M	Sell	1,787,094 -1,056,799	-37%	-$5.65M	2.92%	10
2020 Q2	$9.93M	Buy	+2,843,893	New	+$8.21M	4.83%	8
2020 Q1	–	Sell	-2,315,016	Closed	-$4.54M	–	17
2019 Q4	$4.54M	Buy	2,315,016 +254,748	+12%	+$957K	1.96%	13
2019 Q3	$10.5M	Sell	2,060,268 -510,990	-20%	-$3.09M	3.41%	13
2019 Q2	$18.4M	Sell	2,571,258 -60,000	-2%	-$679K	5.2%	7
2019 Q1	$34.9M	Hold	2,631,258	–	–	12.56%	2
2018 Q4	$20.7M	Buy	2,631,258 +607,889	+30%	+$5.79M	9.5%	4
2018 Q3	$22.4M	Hold	2,023,369	–	–	7.35%	6
2018 Q2	$27.2M	Sell	2,023,369 -88,500	-4%	-$1.11M	9.26%	5
2018 Q1	$27.4M	Sell	2,111,869 -142,633	-6%	-$1.77M	11.37%	3
2017 Q4	$20.7M	Buy	+2,254,502	New	+$19.3M	14.54%	3

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Foresite Capital Management IV's CBAY Position: Q4 2023 in Review

Foresite Capital Management IV sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 1,787,094 shares — an estimated $26.6M sold.

Foresite Capital Management IV first reported a position in CBAY in Q4 2017 and held it in 23 quarters. The position peaked at $34.9M in Q1 2019. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Foresite Capital Management IV reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
Foresite Capital Management IV sold 1,787,094 Cymabay Therapeutics shares in Q4 2023, an estimated $26.6M.
Foresite Capital Management IV first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 23 quarters.
Foresite Capital Management IV's Cymabay Therapeutics position peaked at $34.9M in Q1 2019.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Foresite Capital Management IV's 13F filing for Q4 2023, filed 13 Feb 2024.